← Back to Search

Checkpoint Inhibitor

Rigosertib + Nivolumab for KRAS+ NSCLC Patients Who Progressed on First-Line Treatment

Phase 1 & 2
Recruiting
Led By Rajwanth Veluswamy, MD, MSCR
Research Sponsored by Icahn School of Medicine at Mount Sinai
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 2 years
Awards & highlights

Study Summary

This trial is testing a new combination treatment for lung cancer patients who have a KRAS mutation and have progressed on first-line treatment.

Eligible Conditions
  • Adenocarcinoma
  • Non-Small Cell Lung Cancer
  • End Stage

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~2 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and 2 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Maximal Tolerated Dose (MTD)
Overall Response Rate (ORR)
Secondary outcome measures
Overall Survival (OS) at MTD
Progression Free Survival (PFS)

Trial Design

1Treatment groups
Experimental Treatment
Group I: Rigosertib + NivolumabExperimental Treatment2 Interventions
Rigosertib + Nivolumab in metastatic KRAS+ lung adenocarcinoma patients
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Nivolumab
2014
Completed Phase 3
~4750

Find a Location

Who is running the clinical trial?

Icahn School of Medicine at Mount SinaiLead Sponsor
858 Previous Clinical Trials
524,266 Total Patients Enrolled
Bristol-Myers SquibbIndustry Sponsor
2,638 Previous Clinical Trials
4,128,494 Total Patients Enrolled
48 Trials studying Adenocarcinoma
5,301 Patients Enrolled for Adenocarcinoma
Onconova Therapeutics, Inc.Industry Sponsor
31 Previous Clinical Trials
1,641 Total Patients Enrolled

Media Library

Nivolumab (Checkpoint Inhibitor) Clinical Trial Eligibility Overview. Trial Name: NCT04263090 — Phase 1 & 2
Adenocarcinoma Research Study Groups: Rigosertib + Nivolumab
Adenocarcinoma Clinical Trial 2023: Nivolumab Highlights & Side Effects. Trial Name: NCT04263090 — Phase 1 & 2
Nivolumab (Checkpoint Inhibitor) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04263090 — Phase 1 & 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Rigosertib Plus Nivolumab for KRAS+ NSCLC Patients Who Progressed on First-Line Treatment
Rajwanth Veluswamy 2020. "Rigosertib Plus Nivolumab for KRAS+ NSCLC Patients Who Progressed on First-Line Treatment". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04263090.
~4 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top